Investor Presentaiton
Entering a data-rich period supporting potentially first-in-class/best-
in-class assets with significant commercial potential
cendakimab
Ph III: EoE
SOTYKTU
(deucravacitinib)
Ph III: PSA Induction II
CAMZYOS™
(mavacamten)
Ph III: nHCM
SOTYKTU
(deucravacitinib)
Ph II: Alopecia
Areata (AA)
cendakimab
Ph III: EGE
AR LDD
Ph II: 2L+ mCRPC
Breyanzi
Ph II: RR MZL
Reblozyl
(luspatercept-aamt)
for injection 25mg 75mg
Ph II: TD &
NTD A-Thal
Reblozyl
(luspatercept-aamt)
for injection 25mg 75mg
Ph III: 1L TD MF
anti-CCR8
Reblozyl
(luspatercept-aamt)
for injection 25mg 75mg
Ph III: 1L NTD MDS
Ph I: Solid
Tumors
Ph I: Solid
Tumors
CTLA4 NFPB
Ph II: Solid
Tumors
2024 - 2025
farletuzumab
ecteribulin
Ph II: NSCLC
mezigdomide
Ph III: 2L+ MM
Vd combo
LPA, Antagonist
Ph III: IPF
GPRC5D CAR T
Ph II: RRMM
DGK Inhibitor
alnuctamab
Ph III: 2-4L MM
SOTYKTU
(deucravacitinib)
Ph III: PSA -
Induction I
MYK-224
Ph II: HFPEF
BCL6 LDD
Ph I: Lymphoma
milvexian
Phase III: SSP
mezigdomide
Ph III: 2L+ MM
Kd combo
BET inhib 158
Ph II: 1L MF
farletuzumab
ecteribulin
Ph II: Ovarian
ZEPOSIA.
(ozanimod)
Ph III: Moderate
to severe CD -
Induction II
Opdualag
Ph II: 1L Stage
IV NSCLC
CD19 NEX T
Ph I: Severe
refractory SLE
Opdualag
Ph II: 1L HCC
Opdualag
Ph I/II: 2L+
HCC (Post TKI)
Opdualag
Ph III: 2L/3L+ MSS MCRC
Legend:
Oncology
Hematology
Immunology
1. Japan or Asia study only 2. Confirmatory trial
ll Bristol Myers Squibb" Note: excludes assets pending IND approval: HbF Inducer, BCMA x GPRC5D, CD19 NEXT in MS, & TYK2i-CNS
Timeline represents data readouts or key data to inform clinical development (timeline not to scale)
SOTYKTU
(deucravacitinib)
Ph III: Moderate to severe
SLE Induction I
SOTYKTU
(deucravacitinib)
Ph III: Moderate
to severe SLE -
Induction II
TIGIT
Bispecific
Ph I: Solid
Tumors
iberdomide
Ph III: 2L+ MM
Breyanzi
Ph III: RR FL
(2L high risk)²
Abecma
decabrogene vicleucel)
Ph III: 1L MM
golcadomide
Ph III: 1L LBCL
once daily
milvexian
Ph III: ACS
ONUREG
(azacitidine)
2026 - 2030
Opdualag
elF2B Activator
Phase II: ALS
Ph III: Adj. Melanoma
Phase II/III: Low-or Int. Risk MDS
ZEPOSIA
(ozanimod)
Ph III: Moderate to severe CD - Maintenance
ZEPOSIA
(ozanimod)
Ph III: Moderate to
severe CD
Induction I
Cardiovascular
Neuroscience
SOTYKTU
(deucravacitinib)
Ph III: SjS
LPA1 Antagonist
Ph III: PPF
milvexian
Ph III: AF
anti-MTBR-Tau
Ph II: Alzheimer's
Disease
iberdomide
Ph III: NDMM
Transplant
Maintenance
Not for Product Promotional Use
13View entire presentation